PRAME and melanoma: Interestingly, we were also able to prime CTLs against reovirus-resistant OPM2 cells, suggesting that direct oncolysis was not required, consistent with our previous work using UV-inactivated reovirus which primed melanoma-specific CTLs comparable to replication-competent reovirus.36 With regard to the priming of OPM2-specific CTLs, both U266B and OPM2 express PRAME and MAGE-A1,47 TAA that were recognized by U266B primed-CTLs, therefore, OPM2-primed CTLs could share specificity towards the same myeloma-associated TAA.